TR201900735T4 - Yeni kaynaşık imidazobenzotiyazol bileşikleri. - Google Patents

Yeni kaynaşık imidazobenzotiyazol bileşikleri. Download PDF

Info

Publication number
TR201900735T4
TR201900735T4 TR2019/00735T TR201900735T TR201900735T4 TR 201900735 T4 TR201900735 T4 TR 201900735T4 TR 2019/00735 T TR2019/00735 T TR 2019/00735T TR 201900735 T TR201900735 T TR 201900735T TR 201900735 T4 TR201900735 T4 TR 201900735T4
Authority
TR
Turkey
Prior art keywords
alkyl
imidazo
benzothiazole
butyl
tert
Prior art date
Application number
TR2019/00735T
Other languages
English (en)
Turkish (tr)
Inventor
Shinde Pundlik
Srivastava Sanjay
Tuli Davindar
Rai Deepak
Gj Prashant
Deshpande Shailesh
Gupta Rameshchandra
Chauthaiwale Vijay
Dutt Chaitanya
Original Assignee
Torrent Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torrent Pharmaceuticals Ltd filed Critical Torrent Pharmaceuticals Ltd
Publication of TR201900735T4 publication Critical patent/TR201900735T4/tr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
TR2019/00735T 2014-03-27 2015-03-24 Yeni kaynaşık imidazobenzotiyazol bileşikleri. TR201900735T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1089MU2014 2014-03-27

Publications (1)

Publication Number Publication Date
TR201900735T4 true TR201900735T4 (tr) 2019-02-21

Family

ID=54194050

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/00735T TR201900735T4 (tr) 2014-03-27 2015-03-24 Yeni kaynaşık imidazobenzotiyazol bileşikleri.

Country Status (30)

Country Link
US (2) US9908898B2 (enExample)
EP (1) EP3122755B1 (enExample)
JP (1) JP6480949B2 (enExample)
KR (1) KR102339610B1 (enExample)
CN (1) CN106414458B (enExample)
AR (1) AR099867A1 (enExample)
AU (1) AU2015237840B2 (enExample)
CA (1) CA2943098C (enExample)
CY (1) CY1121147T1 (enExample)
DK (1) DK3122755T3 (enExample)
EA (1) EA029745B9 (enExample)
ES (1) ES2707099T3 (enExample)
HR (1) HRP20190121T1 (enExample)
HU (1) HUE042493T2 (enExample)
IL (1) IL247955B (enExample)
LT (1) LT3122755T (enExample)
MX (1) MX368985B (enExample)
MY (1) MY193041A (enExample)
PH (1) PH12016501903B1 (enExample)
PL (1) PL3122755T3 (enExample)
PT (1) PT3122755T (enExample)
RS (1) RS58324B1 (enExample)
SG (1) SG11201607793RA (enExample)
SI (1) SI3122755T1 (enExample)
SM (1) SMT201900036T1 (enExample)
TR (1) TR201900735T4 (enExample)
TW (1) TWI648282B (enExample)
UA (1) UA121469C2 (enExample)
WO (1) WO2015145336A1 (enExample)
ZA (1) ZA201606598B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2852054T3 (es) 2013-03-15 2021-09-10 Global Blood Therapeutics Inc Compuestos y usos de los mismos para la modulación de hemoglobina
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
TWI648282B (zh) * 2014-03-27 2019-01-21 印度商托仁特生技有限公司 新熔合咪唑苯并噻唑化合物
DE102016209204A1 (de) 2016-05-27 2017-11-30 Robert Bosch Gmbh Vorrichtung zur Regelung mindestens eines Fluidstroms in einem Fahrzeug
KR102630959B1 (ko) * 2016-10-31 2024-01-29 엘지디스플레이 주식회사 유기 화합물과 이를 이용한 발광다이오드 및 유기발광다이오드 표시장치
CN106727538A (zh) * 2017-02-20 2017-05-31 潘连香 一种治疗2型糖尿病的药物组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8724566D0 (en) 1987-10-20 1987-11-25 Roussel Lab Ltd Chemical compounds
GB8908845D0 (en) 1989-04-19 1989-06-07 Roussel Lab Ltd Chemical compounds
AU2381995A (en) * 1994-04-29 1995-11-29 Pharmacia & Upjohn Company Methanol derivatives for treatment of retroviral infections especially hiv infections
WO2002014321A1 (en) * 2000-08-11 2002-02-21 The Regents Of The University Of California Use of stat-6 inhibitors as therapeutic agents
US7601846B2 (en) 2001-06-26 2009-10-13 The Regents Of The University Of California Compounds having activity as inhibitors of apoptosis
JP2006513270A (ja) * 2002-11-25 2006-04-20 ファルマシア・コーポレーション ヘテロアリールスルホニルメチルヒドロキサム酸およびアミド、ならびにプロテアーゼ阻害薬としてのそれらの使用
GB0320244D0 (en) * 2003-05-06 2003-10-01 Aventis Pharma Inc Pyrazoles as inhibitors of tumour necrosis factor
EP1984363A1 (en) * 2006-02-09 2008-10-29 Pfizer Limited Triazolopyridine compounds
TWI648282B (zh) * 2014-03-27 2019-01-21 印度商托仁特生技有限公司 新熔合咪唑苯并噻唑化合物

Also Published As

Publication number Publication date
KR20160129089A (ko) 2016-11-08
JP2017513825A (ja) 2017-06-01
CA2943098C (en) 2022-07-05
JP6480949B2 (ja) 2019-03-13
CN106414458B (zh) 2019-10-29
US20170107233A1 (en) 2017-04-20
EP3122755B1 (en) 2018-11-07
US20180127437A1 (en) 2018-05-10
UA121469C2 (uk) 2020-06-10
PH12016501903B1 (en) 2019-04-26
AU2015237840A1 (en) 2016-09-29
EA201691920A1 (ru) 2017-01-30
TW201613941A (en) 2016-04-16
NZ724342A (en) 2021-02-26
ES2707099T3 (es) 2019-04-02
TWI648282B (zh) 2019-01-21
AU2015237840B2 (en) 2019-06-20
EP3122755A1 (en) 2017-02-01
PL3122755T3 (pl) 2019-05-31
IL247955B (en) 2021-02-28
MX368985B (es) 2019-10-23
PT3122755T (pt) 2019-01-30
EA029745B9 (ru) 2018-08-31
HRP20190121T1 (hr) 2019-03-08
KR102339610B1 (ko) 2021-12-14
CA2943098A1 (en) 2015-10-01
EA029745B1 (ru) 2018-05-31
IL247955A0 (en) 2016-11-30
US9908898B2 (en) 2018-03-06
PH12016501903A1 (en) 2017-01-09
WO2015145336A1 (en) 2015-10-01
SG11201607793RA (en) 2016-10-28
MX2016012535A (es) 2017-05-04
SI3122755T1 (sl) 2019-02-28
DK3122755T3 (en) 2019-02-18
MY193041A (en) 2022-09-23
SMT201900036T1 (it) 2019-02-28
LT3122755T (lt) 2019-02-11
US10227361B2 (en) 2019-03-12
ZA201606598B (en) 2017-11-29
RS58324B1 (sr) 2019-03-29
CN106414458A (zh) 2017-02-15
HUE042493T2 (hu) 2019-07-29
CY1121147T1 (el) 2020-05-29
AR099867A1 (es) 2016-08-24

Similar Documents

Publication Publication Date Title
ES2290538T3 (es) Nuevas imidazopiridinas y su uso.
US10227361B2 (en) Fused imidazobenzothiazole compounds
JP7609790B2 (ja) イミダゾピリジニル化合物及び神経変性障害の処置のためのその使用
CA2559629A1 (en) Pyrazolo[3,4-b]pyridine compound, and its use as a pde4 inhibitor
EP2487175A1 (en) Pharmaceutical product containing aromatic heterocyclic compound
BRPI0811601A2 (pt) composto, método para tratar um distúrbio mediado por jnk em um paciente que tem um distúrbio mediado por jnk, composição farmacêutica, uso do composto e medicamento que compreende o composto.
CN102656172A (zh) 8-氧代二氢嘌呤衍生物
US20190127381A1 (en) Substituted fused pyrimidinone compounds
ES2731429T3 (es) Compuestos de indanilurea inhibidores de MAP quinasa P38
NZ724342B2 (en) Novel fused imidazobenzothiazole compounds
CN109280028B (zh) 喹啉类化合物及其在dpp-4酶抑制剂的应用
CN104003990A (zh) 杂环胺类Hedgehog信号通路抑制剂